November 8, 2001 - NATA ONLINE

08 Nov 2001

Recombinant activated factor VII (RFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices.

This is a new open-label study, which showed efficacy of rFVIIa in normalising prothrombin time and effective control of bleeding esophageal varices in cirrhotic patients,...

Published on Aug 2001

Are leukocytes in salvaged washed autologous blood harmful for the recipient? The results of a pilot study.

Innerhofer P, Wiedermann FJ, Tiefenthaler W, et al.

Anesth Analg 2001;93(3):566-572.

Review by E. Hansen

Published on Jul 2001

Recombinant activated factor VII (RFVIIa): Characterization, manufacturing, and clinical development.

Jurlander B, Thim L, Klausen NK, et al.

Semin Thromb Hemostasis 2001;27(4):373-383.

Review by M. Aldouri

Published on Aug 2001

Development of an animal model for assessment of the hemostatic efficacy of fibrin sealant in vascular surgery.

Kheirabadi BS, Pearson R, Rudnicka K, et al.

J Surg Res 2001;100(1):84-92.

Review by R. K. Spence

Published on Jul 2001

Radiofrequency ablation of liver tumours.

Kormann J, Ockert D, Bunk A

Zbl Chir 2001;126(8):576-585.

Review by R. K. Spence

NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis

MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.

Sitemap

Contact us

SUBSCRIBE TO OUR NEWSLETTER

Consent Management Platform by Real Cookie Banner

Sitemap

Contact us

Follow us

SUBSCRIBE TO OUR NEWSLETTER